Merger Pending Sponsor buyer
Relativity Acquisition Corp. and Instinct Bio Technical Company merger
US$225m consideration
Announced 28 Feb 2025
Advisers
Instinct Bio Technical Company
Target
- Financial adviser
- Everise Concepts PLT
- Legal adviser
- Darryl, Edward & Co.
- Tax adviser
Relativity Acquisition Corp.
Acquirer
- Legal adviser
- Barnett & Linn
- Fairness opinion
- EntrepreneurShares
- Japanese diligence
- Aquaxis
- Target
- Instinct Bio Technical Company
- Acquirer
- Relativity Acquisition Corp.
- Sponsor
- Relativity Acquisition Sponsor
- Target based in
- Cayman Islands
- Buyer based in
- United States
- Sector
- Biotech
In the league tables
Similar deals
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
- Ipsen acquisition of Memo Therapeutics Jul 2026 · US$231m · Biotech
- Bayer acquisition of Perfuse Therapeutics May 2026 · US$300m · Biotech
- Gyre Therapeutics acquisition of Cullgen Mar 2026 · US$300m · Biotech
Sources
- 5 Mar 2026 Definitive merger proxy statement (DEFM14A), Relativity Acquisition Corp sec.gov